Abstract
Background Thoracic aortic disease is an important cause of morbidity and mortality in the US, and aortic diameter is a heritable contributor to risk. Could a polygenic prediction of ascending aortic diameter improve detection of aortic aneurysm?
Methods Deep learning was used to measure ascending thoracic aortic diameter in 49,939 UK Biobank participants. A genome-wide association study (GWAS) was conducted in 39,524 participants and leveraged to build a 1.1 million-variant polygenic score with PRScs-auto. Aortic diameter prediction models were built with the polygenic score (“AORTA Gene”) and without it. The models were tested in a held-out set of 4,962 UK Biobank participants and externally validated in 5,469 participants from Mass General Brigham Biobank (MGB), 1,298 from the Framingham Heart Study (FHS), and 610 participants from All of Us.
Results In each test set, the AORTA Gene model explained more of the variance in thoracic aortic diameter compared to clinical factors alone: 39.9% (95% CI 37.8-42.0%) vs 29.2% (95% CI 27.1-31.4%) in UK Biobank, 36.5% (95% CI 34.4-38.5%) vs 32.5% (95% CI 30.4-34.5%) in MGB, 41.8% (95% CI 37.7-45.9%) vs 33.0% (95% CI 28.9-37.2%) in FHS, and 34.9% (95% CI 28.8-41.0%) vs 28.9% (95% CI 22.9-35.0%) in All of Us. AORTA Gene had a greater AUROC for identifying diameter ≥4cm in each test set: 0.834 vs 0.765 (P=7.3E-10) in UK Biobank, 0.808 vs 0.767 in MGB (P=4.5E-12), 0.856 vs 0.818 in FHS (P=8.5E-05), and 0.827 vs 0.791 (P=7.8E-03) in All of Us.
Conclusions Genetic information improved estimation of thoracic aortic diameter when added to clinical risk factors. Larger and more diverse cohorts will be needed to develop more powerful and equitable scores.
Competing Interest Statement
Dr. Ellinor has received sponsored research support from Bayer AG, IBM Health, Bristol Myers Squibb and Pfizer. Dr. Ellinor has also served on advisory boards or consulted for Bayer AG, MyoKardia and Novartis. The Broad Institute has filed for a patent on an invention from Drs. Ellinor, Lindsay, and Pirruccello related to a previous genetic risk predictor for aortic disease. Remaining authors report no disclosures.
Clinical Trial
N/A. This study was not a clinical trial.
Funding Statement
Organizations that provided financial support had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. Dr. Pirruccello is supported by National Institutes of Health (NIH) K08HL159346. Dr. Lin is supported by the NIH grant U01AG068221. Dr. Kany is supported by the Walter-Benjamin Fellowship from the Deutsche Forschungsgemeinschaft (521832260). Dr. Raghavan is supported by the John S. LaDue Memorial Fellowship in Cardiovascular Medicine from Harvard Medical School. Dr. Benjamin is supported by NIH grants R01HL128914, R01HL092577, R01HL141434, and U54HL120163; and American Heart Association (AHA) grant 18SFRN34110082. Dr. Lindsay is supported by the Fredman Fellowship for Aortic Disease and the Toomey Fund for Aortic Dissection Research and has received salary support from Bayer AG. Dr. Ellinor is supported by grants from the NIH (R01HL092577, 1R01HL157635), from the AHA Strategically Focused Research Networks (18SFRN34110082), and from the European Union (MAESTRIA 965286). The All of Us Research Program is supported by the National Institutes of Health, Office of the Director: Regional Medical Centers: 1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IAA #: AOD 16037; Federally Qualified Health Centers: HHSN 263201600085U; Data and Research Center: 5 U2C OD023196; Biobank: 1 U24 OD023121; The Participant Center: U24 OD023176; Participant Technology Systems Center: 1 U24 OD023163; Communications and Engagement: 3 OT2 OD023205; 3 OT2 OD023206; and Community Partners: 1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 OD025337; 1 OT2 OD025276. In addition, the All of Us Research Program would not be possible without the partnership of its participants. From the Framingham Heart Study of the National Heart Lung and Blood Institute of the National Institutes of Health and Boston University School of Medicine, this project has been funded in whole or in part with Federal funds from the National Heart Lung and Blood Institute, Department of Health and Human Services, under Contract No. 75N92019D00031.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK Biobank analyses were considered exempt by the UCSF Institutional Review Board (IRB), #22-37715. UK Biobank analyses were conducted under application #41664. Each All of Us biobank participant provided written informed consent. The All of Us analyses were considered exempt by the UCSF IRB, #22-37715. The MGB study protocols were approved with a waiver of informed consent by the Mass General Brigham IRB. All FHS participants provided written informed consent, and the FHS imaging analyses were previously approved by the IRB of the Boston University Medical Center. The FHS analyses were also approved by the MGB IRB.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Computed scores are returned to UK Biobank, where data are made available by UK Biobank to researchers from research institutions with genuine research inquiries, following IRB and UK Biobank approval. FHS data are made available to researchers with approved research applications. The dbGAP study accession number used for FHS validation was #phv00076329.v1.p5 for ascending aortic diameter. MGB data are available to MGB investigators; external collaboration requests can be initiated through https://biobank.massgeneralbrigham.org/for-researchers. Upon publication, the complete set of AORTA Score covariates and their weights will be available as R programs at github.com/carbocation/genomisc and the polygenic score weights will be available on the Polygenic Score Catalog (pgscatalog.org).
